|Classification and external resources|
Analgesic nephropathy is injury to the kidney caused by analgesic medications such as aspirin, phenacetin, and paracetamol. The term usually refers to damage induced by excessive use of combinations of these medications, especially combinations that include phenacetin. It may also be used to describe kidney injury from any single analgesic medication.
The specific kidney injuries induced by analgesics are renal papillary necrosis and chronic interstitial nephritis. They appear to result from decreased blood flow to the kidney, rapid consumption of antioxidants, and subsequent oxidative damage to the kidney. This kidney damage may lead to progressive chronic renal failure, abnormal urinalysis results, high blood pressure, and anemia. A small proportion of individuals with analgesic nephropathy may develop end-stage kidney disease.
Analgesic nephropathy was once a common cause of kidney injury and end-stage kidney disease in parts of Europe, Australia, and the United States. In most areas, its incidence has declined sharply since the use of phenacetin fell in the 1970s and 1980s.
Analgesics are a class of medications widely used in the treatment of pain. They include aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), as well as the antipyretics paracetamol (known as acetaminophen in the United States) and phenacetin. Introduced in the late 19th century, phenacetin was once a common component of mixed analgesics in parts of Europe, Australia, and the United States. These combined analgesics contained aspirin or other NSAID with phenacetin, paracetamol, or salicylamide, and caffeine or codeine.
In the 1950s, Spühler and Zollinger reported an association between kidney injury and the chronic use of phenacetin. They noted that chronic users of phenacetin had an increased risk of developing specific kidney injuries, namely renal papillary necrosis and chronic interstitial nephritis. This condition was dubbed analgesic nephropathy and was attributed to phenacetin, although no absolute causative role was demonstrated. With further reports of the increased risk of kidney injury with prolonged and excessive phenacetin use, however, phenacetin was banned in several countries between the 1960s and 1980s.
As the use of phenacetin declined, so too did the prevalence of analgesic nephropathy as a cause of end-stage renal disease. Data from Switzerland, for example, demonstrated a decline in the prevalence of analgesic nephropathy among patients with end-stage renal disease, from 28% in 1981 to 12% in 1990. An autopsy study performed in Switzerland suggested that the prevalence of analgesic nephropathy in the general population has likewise decreased; the prevalence was 3% in 1980 and 0.2% in 2000.
While these data demonstrate that analgesic nephropathy has been all but eliminated in some regions, in other regions the condition persists. Notably, in Belgium, the prevalence of analgesic nephropathy among dialysis patients was 17.9% in 1984 and 15.6% in 1990. Michielsen and de Schepper have suggested that analgesic nephropathy persists among Belgian dialysis patients not due to non-phenacetin analgesics, but because Belgium accepts a higher proportion of elderly patients for dialysis. According to these authors, a greater proportion have analgesic nephropathy because a greater percentage of Belgian dialysis patients have been exposed to long-term use of phenacetin.
The scarring of the small blood vessels, called capillary sclerosis, is the initial lesion of analgesic nephropathy. Found in the renal pelvis, ureter, and capillaries supplying the nephrons, capillary sclerosis is thought to lead to renal papillary necrosis and, in turn, chronic interstitial nephritis.
How phenacetin and other analgesics lead to this damage is incompletely understood. It is currently thought that the renal toxicities of NSAIDs and the antipyretics phenacetin and paracetamol may combine to give rise to analgesic nephropathy. A committee of investigators reported in 2000 that there was insufficient evidence to suggest that non-phenacetin analgesics by themselves are associated with analgesic nephropathy.
Aspirin and NSAIDs
Proper kidney function depends upon adequate blood flow to the kidney. Kidney blood flow is a complex, tightly regulated process that relies on a number of hormones and other small molecules, such as prostaglandins. Under normal circumstances, prostaglandin E2 (PGE2) produced by the kidney is necessary to support adequate blood flow to the kidney. Like all prostaglandins, PGE2 synthesis depends upon the cyclooxygenases.
Aspirin and other NSAIDs are inhibitors of the cyclooxygenases. In the kidney, this inhibition results in decreased PGE2 concentration causing a reduction in blood flow. Because blood flow to the kidney first reaches the renal cortex (outside) and then the renal medulla (inside), the deeper structures of the kidney are most sensitive to decreased blood flow. Thus the innermost structures of the kidney, called the renal papillae, are especially dependent on prostaglandin synthesis to maintain adequate blood flow. Inhibition of cyclooxygenases therefore rather selectively damages the renal papillae, increasing the risk of renal papillary necrosis.
Most healthy kidneys contain enough physiologic reserve to compensate for this NSAID-induced decrease in blood flow. However, those subjected to additional injury from phenacetin or paracetamol may progress to analgesic nephropathy.
Phenacetin and paracetamol
Paracetamol is the major metabolite of phenacetin and may contribute to kidney injury through a specific mechanism. In cells of the kidney, cyclooxygenases catalyse the conversion of paracetamol into N-acetyl-p-benzoquinoneimine (NAPQI). NAPQI depletes glutathione via non-enzymatic conjugation to glutathione, a naturally occurring antioxidant. With depletion of glutathione, cells of the kidney become particularly sensitive to oxidative damage.
|Urinary tract infection||30-60%|
Common findings in patients with analgesic nephropathy include headache, anemia, high blood pressure (hypertension), and white blood cells in the urine (pyuria). Some individuals with analgesic nephropathy may also have protein in their urine (proteinuria).
Diagnosis is traditionally based on the clinical findings above in combination with excessive analgesic use. It is estimated that between 2 and 3 kg each of phenacetin or aspirin must be consumed before evidence of analgesic nephropathy becomes clinically apparent.
Once suspected, analgesic nephropathy can be confirmed with relative accuracy using computed tomography (CT) imaging without contrast. One trial demonstrated that the appearance of papillary calcifications on CT imaging was 92% sensitive and 100% specific for the diagnosis of analgesic nephropathy.
Complications of analgesic nephropathy include pyelonephritis and end-stage kidney disease. Risk factors for poor prognosis include recurrent urinary tract infection and persistently elevated blood pressure. Analgesic nephropathy also appears to increase the risk of developing cancers of the urinary system.
Treatment of analgesic nephropathy begins with the discontinuation of analgesics, which often halts the progression of the disease and may even result in normalization of kidney function.
The term analgesic nephropathy usually refers to damage induced by excessive use of combinations of these medications, specifically combinations that include phenacetin. For this reason, it is also called analgesic abuse nephropathy. Murray prefers the less judgmental analgesic-associated nephropathy. Both terms are abbreviated to the acronym AAN, by which the condition is also commonly known.
- McLaughlin JK, Lipworth L, Chow WH, Blot WJ (September 1998). "Analgesic use and chronic renal failure: a critical review of the epidemiologic literature". Kidney Int. 54 (3): 679–86. doi:10.1046/j.1523-1755.1998.00043.x. PMID 9734593.
- de Broe, Marc E (2008). "Analgesic nephropathy". In Curhan, Gary C (ed.). UpToDate. Waltham, MA.
- Spühler O, Zollinger HU (1953). "Die chronisch-interstitielle Nephritis.". Z Klin Med (in German) 151 (1): 1–50. PMID 13137299.
- Brunner FP, Selwood NH (1994). "End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee". Nephrol. Dial. Transplant. 9 (10): 1371–6. PMID 7816247.
- Mihatsch MJ, Khanlari B, Brunner FP (November 2006). "Obituary to analgesic nephropathy--an autopsy study". Nephrol. Dial. Transplant. 21 (11): 3139–45. doi:10.1093/ndt/gfl390. PMID 16891638.
- Elseviers MM, de Broe ME (1994). "Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures". Nephrol. Dial. Transplant. 9 (1): 41–6. PMID 8177475.
- Noels LM, Elseviers MM, de Broe ME (1995). "Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium". Nephrol. Dial. Transplant. 10 (2): 167–74. PMID 7753450.
- Michielsen P, de Schepper P (March 2001). "Trends of analgesic nephropathy in two high-endemic regions with different legislation". J. Am. Soc. Nephrol. 12 (3): 550–6. PMID 11181803.
- Mihatsch MJ, Hofer HO, Gudat F, Knüsli C, Torhorst J, Zollinger HU (December 1983). "Capillary sclerosis of the urinary tract and analgesic nephropathy". Clin. Nephrol. 20 (6): 285–301. PMID 6641031.
- Feinstein AR, Heinemann LA, Curhan GC, et al. (December 2000). "Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy". Kidney Int. 58 (6): 2259–64. doi:10.1046/j.1523-1755.2000.00410.x. PMID 11115060.
- Bach PH, Hardy TL (October 1985). "Relevance of animal models to analgesic-associated renal papillary necrosis in humans". Kidney Int. 28 (4): 605–13. doi:10.1038/ki.1985.172. PMID 3910912.
- Mohandas J, Duggin GG, Horvath JS, Tiller DJ (November 1981). "Metabolic oxidation of acetaminophen (paracetamol) mediated by cytochrome P-450 mixed-function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney". Toxicol. Appl. Pharmacol. 61 (2): 252–9. doi:10.1016/0041-008X(81)90415-4. PMID 6798713.
- Duggin GG (July 1996). "Combination analgesic-induced kidney disease: the Australian experience". Am. J. Kidney Dis. 28 (1 Suppl 1): S39–47. doi:10.1016/S0272-6386(96)90568-5. PMID 8669429.
- Murray TG, Goldberg M (January 1978). "Analgesic-associated nephropathy in the U.S.A.: epidemiologic, clinical and pathogenetic features". Kidney Int. 13 (1): 64–71. doi:10.1038/ki.1978.9. PMID 713270.
- Nanra RS, Stuart-Taylor J, de Leon AH, White KH (January 1978). "Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia". Kidney Int. 13 (1): 79–92. doi:10.1038/ki.1978.11. PMID 362034.
- de Broe ME, Elseviers MM (February 1998). "Analgesic nephropathy". N. Engl. J. Med. 338 (7): 446–52. doi:10.1056/NEJM199802123380707. PMID 9459649.
- Elseviers MM, De Schepper A, Corthouts R, et al. (October 1995). "High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure". Kidney Int. 48 (4): 1316–23. doi:10.1038/ki.1995.416. PMID 8569094.
- Maisonneuve P, Agodoa L, Gellert R, et al. (January 2000). "Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study". Am. J. Kidney Dis. 35 (1): 157–65. doi:10.1016/S0272-6386(00)70316-7. PMID 10620560.
- Linton AL (October 1972). "I. Recognition of the problem of analgesic nephropathy". Can Med Assoc J 107 (8): 749–51. PMC 1941002. PMID 4638849.
- Blohmé I, Johansson S (November 1981). "Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy". Kidney Int. 20 (5): 671–5. doi:10.1038/ki.1981.192. PMID 7045494.